Laniquidar

Systematic (IUPAC) name

methyl 11-(1-{2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl}piperidin-4-ylidene)-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate
Clinical data
Identifiers
CAS Registry Number	197509-46-9
ATC code	None
PubChem	CID 6450806
ChemSpider	4953357
UNII	K3FRN4DDOY^Y
Chemical data
Formula	C₃₇H₃₆N₄O₃
Molecular mass	584.70 g/mol
SMILES COC(=O)C1=CN=C2N1CCC3=CC=CC=C3C2=C4CCN(CC4)CCC5=CC=C(C=C5)OCC6=NC7=CC=CC=C7C=C6
InChI InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3 Key:TULGGJGJQXESOO-UHFFFAOYSA-N
Y (what is this?) (verify)

Laniquidar (INN) is a P-glycoprotein inhibitor undergoing clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).^[1]

References

↑ Ross, DD (2004). "Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome". Best practice & research. Clinical haematology 17 (4): 641–51. doi:10.1016/j.beha.2004.08.014. PMID 15494300.